Soleno Therapeutics (NASDAQ:SLNO) Cut to “Hold” at Robert W. Baird

Robert W. Baird lowered shares of Soleno Therapeutics (NASDAQ:SLNO) from a strong-buy rating to a hold rating in a research report released on Monday morning,Zacks.com reports.

Several other research analysts also recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Soleno Therapeutics in a report on Thursday, January 22nd. Wells Fargo & Company dropped their target price on shares of Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating for the company in a report on Friday, February 27th. Cantor Fitzgerald downgraded shares of Soleno Therapeutics from an “overweight” rating to a “hold” rating and dropped their target price for the stock from $123.00 to $53.00 in a report on Monday. Lifesci Capital downgraded shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday. Finally, Wolfe Research downgraded shares of Soleno Therapeutics from an “outperform” rating to a “hold” rating in a report on Tuesday. Four equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $89.20.

Soleno Therapeutics Trading Up 0.5%

Shares of SLNO stock opened at $52.60 on Monday. Soleno Therapeutics has a 1 year low of $29.43 and a 1 year high of $90.32. The firm has a fifty day moving average price of $38.39 and a 200-day moving average price of $47.83. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.80 and a quick ratio of 5.55. The company has a market cap of $2.72 billion, a price-to-earnings ratio of 228.71 and a beta of -2.81.

Soleno Therapeutics (NASDAQ:SLNO) last issued its quarterly earnings data on Wednesday, February 25th. The company reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.16. The business had revenue of $91.73 million for the quarter, compared to the consensus estimate of $88.55 million. As a group, equities analysts predict that Soleno Therapeutics will post -3.72 earnings per share for the current year.

Institutional Trading of Soleno Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Janus Henderson Group PLC lifted its stake in Soleno Therapeutics by 18.5% in the 4th quarter. Janus Henderson Group PLC now owns 7,178,354 shares of the company’s stock worth $332,302,000 after purchasing an additional 1,122,015 shares in the last quarter. Wellington Management Group LLP lifted its stake in Soleno Therapeutics by 43.7% in the 4th quarter. Wellington Management Group LLP now owns 3,322,799 shares of the company’s stock worth $153,846,000 after purchasing an additional 1,010,704 shares in the last quarter. Vanguard Group Inc. lifted its stake in Soleno Therapeutics by 9.0% in the 4th quarter. Vanguard Group Inc. now owns 3,060,361 shares of the company’s stock worth $141,695,000 after purchasing an additional 253,212 shares in the last quarter. Avoro Capital Advisors LLC lifted its stake in Soleno Therapeutics by 12.5% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,900,000 shares of the company’s stock worth $134,270,000 after purchasing an additional 322,223 shares in the last quarter. Finally, State Street Corp lifted its stake in Soleno Therapeutics by 21.9% in the 4th quarter. State Street Corp now owns 2,649,626 shares of the company’s stock worth $122,678,000 after purchasing an additional 476,590 shares in the last quarter. Hedge funds and other institutional investors own 97.42% of the company’s stock.

Soleno Therapeutics News Roundup

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Neurocrine acquisition drives rally — Neurocrine agreed to acquire Soleno in a cash deal near $53/share (reported deal value ~$2.9B), adding VYKAT (DCCR) to its portfolio; that takeover/offer price is the main catalyst lifting SLNO shares this week. Zacks: Soleno Therapeutics Stock Rallies
• Neutral Sentiment: EU marketing application withdrawn ahead of takeover — Soleno voluntarily withdrew its European marketing application for the rare‑disease drug as Neurocrine sharpens focus on the U.S. market; this reduces near‑term EU optionality but appears tactical given the pending acquisition. Reuters: Soleno withdraws EU application
• Neutral Sentiment: Mixed analyst stance — HC Wainwright reiterated a “neutral” rating and cut its price target to $53 (from $100), signaling analysts are aligning targets close to the deal price; that limits upside absent a competing bidder or a higher offer. Benzinga coverage
• Negative Sentiment: Class‑action over alleged misstatements — Multiple plaintiff firms have filed/announced investigations and are soliciting lead plaintiffs for a securities‑fraud suit covering March 26–Nov 4, 2025 (alleging misstatements about the DCCR Phase 3 program); May 5, 2026 is the lead‑plaintiff deadline. This creates legal and reputational overhang that can pressure the stock and complicate the deal transition. PR Newswire: Deadline in securities fraud class action
• Negative Sentiment: Multiple downgrades trim expectations — A string of firms (Wolfe, TD Cowen, Piper Sandler, Baird, Cantor Fitzgerald, Lifesci, etc.) cut ratings/targets to “hold” or similar and trimmed price targets toward ~$53, reflecting deal‑price anchoring and reduced standalone upside; analyst caution can weigh on buyers absent a higher bid or new data. Zacks: analyst downgrade coverage

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.